Glucagon-Like Peptide-1 Agonist (GLP-1)

Phase 2Small molecule

Glucagon-Like Peptide-1 Agonist (GLP-1) is one of 69 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Alcohol Use DisorderNot yet recruiting

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Alcohol Use DisorderPhase 2

Not yet recruiting

Competition

Competitive Landscape

150 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Retatrutide

Eli Lilly

Phase 3

1 2

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 3

GZR18

GGan & Lee Pharmaceuticals.

Phase 3

5 4

HDM1002

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

3 5

Elecoglipron

AstraZeneca

Phase 3

5 6

Dorzagliatin

HHua Medicine Limited

Phase 3

—7

TG103

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 3

2 8

Adenocard

Astellas

Preclinical

1 9

NOVOLIN R

Novo Nordisk

Preclinical

1 10

Dostinex

Pfizer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Recruiting

Obesity & Overweight

NCT07702461

Q3 2028

Phase 2Not yet recruiting

Alcohol Use Disorder

NCT07249554

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus2 trials

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03249506·25,358 enrolled

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03492580·714,582 enrolled

Obesity & Overweight1 trial

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Recruiting·OOhio State University··NCT07702461·300 enrolled

Alcohol Use Disorder1 trial

Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder

Not yet recruiting·JJohns Hopkins University·Phase 2·NCT07249554·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Glucagon-Like Peptide-1 Agonist (GLP-1). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucagon-Like Peptide-1 Agonist (GLP-1) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucagon-Like Peptide-1 Agonist (GLP-1). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

Glucagon-Like Peptide-1 Agonist (GLP-1)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2028

Trials by Indication[1]

Type 2 Diabetes Mellitus2 trials

Obesity & Overweight1 trial

Alcohol Use Disorder1 trial

References

Drug Info

Quick Facts

Related News